On Tuesday (November 10), one stone stirred up thousands of waves, and the style of US stocks continued to change.The closing price was mixed.The Dow closed up 0.9%, the Nasdaq fell 1.37%, and the S & P 500 fell 0.14%.

Sectors related to the economic recovery continue to be popular, cyclical sectors are bright, and the pharmaceutical sector continues to be strong, benefiting from the continued downturn of home-isolated sectors and big technologies.

Stocks that climb to the top

Those with a relatively large annual increase areManufacturer of aluminum products for aircraft and automobile$Arconic Inc (ARNC.US) $It rose 7.51% on Tuesday, an annual increase of more than 307%.

Arconic reported quarterly earnings of $.05 a share, 64.29% below analysts' expectations of $0.14, and quarterly revenue of $1.42 billion, 1.8% higher than analysts' estimates of $1.39 billion.

Denali: a biotechnology company that challenges Parkinson's and Alzheimer's disease.

Neurodegenerative diseases drug research and development company$Denali Therapeutics (DNLI.US) $Shares rose 7.51% on Tuesday, an annual increase of more than 244%.

Neurodegenerative diseases (Neurodegeneration) are disorders caused by gradual loss of neuronal structure or function or even death. Common diseases include Alzheimer's disease, Parkinson's disease,Huntington's diseaseAnd ALS (amyotrophic lateral sclerosis)The cause of this kind of disease is not clear and can not be cured, which is a serious threat to human health and daily life.

In the past few decades, progress in drug research and development in this field has been very limited.

Denali is working on seven new drugs, mainly in Parkinson's, Alzheimer's and ALS. The new drugs under development are mainly based on three pathways: lysosomal function (lysosomal enzyme), glial cells (Glial Biology) and cell homeostasis (Cellular Homeostasis).

On the 10th, Denali announced that itTransport VehicleTechnology in ETV:IDS (DNL310)Conceptual biomarker evidence was obtained in stage 1-2 of the study, which can be used in Hunter syndrome (MPS II).Potential treatment. The technology is designed to allow patients to pass throughAfter intravenous injection, large therapeutic molecules such as antibodies, enzymes, proteins and oligonucleotides are effectively transferred to the blood-brain barrier to achieve the therapeutic effect.

There are also pharmaceutical companies with an annual increase of more than 200%.$BioNTech SE (BNTX.US) $, up 7.6% on Tuesday

Those with a relatively large daily increase are$Herc Rentals Inc (HRI.US) $It rose 11.16% on Tuesday.

Genetic Diseases and Epilepsy treatment Research and Development Company$Stoke Therapeutics (STOK.US) $It rose 9.52% on Tuesday. Engaged in consumer credit and services$Nelnet (NNI.US) $up 8.84%, real estate development and management company$Saint Joe (JOE.US) $Up 8.13%, service providers of construction, energy equipment and transport products$Arcosa, Inc. (ACA.US) $Up 7.6%

Other areas of concern areOne of the telecom service giants$Verizon Communications Inc (VZ.US) $Up 2% yesterday, the media industry$Comcast Corp (CMCSA.US) $、News Corporation Class B (NWS.US) $Aerospace and transport plate$Honeywell International Inc (HON.US) $ 、$CSX Corp (CSX.US) $、$Norfolk South (NSC.US) $The share price went up.

The Eye of Storm that changes the style of the Market

BioNTech, which jointly released the interim data of COVID-19 's vaccine phase III study with Pfizer Inc a few days ago, rose 7.6% on the 10th, an annual increase of 232%, an all-time high.

Before the plate$BioNTech SE (BNTX.US) $The financial results for the third quarter ended September 30, 2020 are announced.

BioNTech's revenue in the third quarter was 67.458 million euros, up 135% from a year earlier. The cost of R & D was 228 million euros, compared with 50.396 million euros in the same period last year.The net loss was 210 million euros, compared with 30.103 million euros in the same period last year; the diluted basic loss per share of shareholders belonging to the parent company was 0.88 euros, compared with a loss of 0.14 euros in the same period last year.

On Tuesday, Dr. Fauci of the National Institutes of Health said that emergency use authorization for Pfizer Inc / BioNTech vaccine could arrive in about a week.

Earlier, BioNTech provided the latest development of COVID-19 's mRNA vaccine program BNT162.

BioNTech and$Pfizer Inc (PFE.US) $Announced commercial supply agreements with Canada, Japan, the United Kingdom, the United States and the European Union for 2020 and 2021, totaling more than 570 million doses, including the option to purchase an additional 600 million doses.

According to supply forecasts, the company expects to supply up to 50 million doses of vaccine worldwide in 2020 and produce 1.3 billion doses by 2021.

BioNTech has also completed the acquisition of GMP certified plant facilities in Marburg, Germany, and plans to increase BNT162's production capacity for commercial supply in 2021.